DEA Comments Gaffe
The DEA (Drug Enforcement Agency) has ordained its decree: Another year, another decrease in the production quota for prescription opioids.
Stop Sensationalizing Respiratory Viruses
Instead of using sensationalistic terminology, it would be more helpful to focus on accurate information when discussing respiratory viruses.
Elderly Medical Debt Leads to Financial Ruin
The prospect of dying broke looms for the boomer generation as they face financial hardship due to soaring healthcare costs.
Literature Made Me a Doctor
As a poet and scholar of the health humanities, I stand in the overlapping field of healing and poetic practices.
The Pollution and Alzheimers Connection
People who were exposed to more pollution did worse on cognitive tests, and the outer layer of their brain, the ...
Illegal Immigration Burdens the c
One area that is particularly affected is the American healthcare system, both in terms of financial strain and clinical outcomes.
Mental Health Courts Struggle to Fulfill Mission
Advocates, attorneys, clinicians, and researchers say mental health courts struggle to live up to their promise.
ProPublica Adds Ownership Information to Nursing Home Database
The quality of care that residents receive in a nursing home can be profoundly affected by who owns it, studies ...
Physicians: Write Legal Briefs
In recent years, there has been an increasing need for physicians to participate in complex healthcare legal cases by writing ...
Opioid Settlements: “Cash Cow”
“It’s heartbreaking to see what the government is doing with this money. Putting it in places they really don’t need ...
What’s Next for the Obesity Industrial Complex
The future of the obesity industry is not in novel drugs or new forms of therapy, but in combining existing ...
Black Swans of Health Policy
Don’t worry about the healthcare laws. Worry about the changing legal interpretations of existing healthcare laws.
FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation
Clinicians increasingly encounter patients using or requesting peptide-based therapies sourced through compounding pharmacies. The U.S. Food and Drug Administration has identified a subset of bulk drug substances, including certain peptides, that may present significant safety risks when used in compounded formulations. The clinical question is whether these regulatory signals reflect meaningful patient-level risk and how they should influence prescribing behavior. This matters because compounded peptides often sit outside traditional approval pathways, creating uncertainty around quality, dosing consistency, and safety. Understanding...
Read more